You are viewing the site in preview mode
Skip to main content
|
Characteristics of studies
|
N (%)
|
|---|
|
Year of study
|
|
Before Year 2000
|
3 (2.0)
|
|
Year 2000–2010
|
32 (21.6)
|
|
Year 2011–2020
|
113 (76.4)
|
|
Continent of study
|
|
Asia
|
58 (39.2)
|
|
Europe
|
40 (27.0)
|
|
North America
|
40 (27.0)
|
|
Australia
|
3 (2.0)
|
|
South America
|
3 (2.0)
|
|
Cross-continents
|
4 (2.7)
|
|
Country of study
|
|
USA
|
33 (22.3)
|
|
China
|
17 (11.5)
|
|
Italy
|
11 (7.4)
|
|
Canada
|
6 (4.1)
|
|
Netherlands
|
6 (4.1)
|
|
Korea
|
6 (4.1)
|
|
Singapore
|
5 (3.4)
|
|
Australia
|
3 (2.0)
|
|
Hong Kong
|
4 (2.7)
|
|
Japan
|
4 (2.7)
|
|
Multi-countries
|
5 (3.4)
|
|
Others
|
48 (32.4)
|
|
Study design
|
|
Cross-sectional study
|
92 (62.1)
|
|
Cohort study
|
50 (33.8)
|
|
Prospective cohort study
|
21 (14.2)
|
|
Retrospective cohort study
|
29 (19.5)
|
|
Record linkage study
|
2 (1.4)
|
|
Prospective record linkage study
|
1 (0.7)
|
|
Retrospective record linkage study
|
1 (0.7)
|
|
Randomized controlled trials
|
4 (2.7)
|
|
Patient population
|
|
≤ 500
|
37 (25)
|
|
501–1000
|
21 (14.2)
|
|
1001 – 5000
|
43 (29.1)
|
|
5001 – 10,000
|
11 (7.4)
|
|
10,001–50,000
|
17 (11.5)
|
|
50,001–100,000
|
7 (4.7)
|
|
100,001–500,000
|
9 (6.1)
|
|
500,000 – 1000,000
|
2 (1.4)
|
|
> 1000,000
|
1 (0.7)
|
|
Type 2 diabetes subgroups
|
|
Adult diabetics (across all age ranges)
|
137 (92.6)
|
|
Elderly (≥ 65 years old)
|
8 (5.4)
|
|
Young (≤ 40 years old)
|
2 (1.4)
|
|
Women with singleton pregnancy
|
1 (0.7)
|
|
Study setting (Healthcare)a
|
|
Primary
|
40 (27.0)
|
|
Tertiary
|
68 (45.9)
|
|
Mixed
|
10 (6.8)
|
|
Not applicable or not specified
|
30 (20.3)
|
|
Data source
|
|
Primary
|
70 (47.3)
|
|
Secondary
|
76 (51.4)
|
|
Mixed (Primary and Secondary)
|
2 (1.4)
|
- a – There were no studies performed in secondary healthcare settings
